Prelude Capital Management’s Array Biopharma Inc ARRY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q3 | – | Sell |
-564,244
| Closed | -$26.1M | – | 2281 |
|
|
2019
Q2 | $26.1M | Buy |
+564,244
| New | +$15.8M | 1.29% | 10 |
|
|
2019
Q1 | – | Sell |
-1,927
| Closed | -$27K | – | 2374 |
|
|
2018
Q4 | $27K | Sell |
1,927
-5,281
| -73% | -$80.1K | ﹤0.01% | 1208 |
|
|
2018
Q3 | $110K | Buy |
7,208
+3,693
| +105% | +$56.6K | 0.01% | 935 |
|
|
2018
Q2 | $59K | Sell |
3,515
-42,737
| -92% | -$680K | ﹤0.01% | 1082 |
|
|
2018
Q1 | $755K | Buy |
46,252
+8,758
| +23% | +$140K | 0.05% | 342 |
|
|
2017
Q4 | $480K | Buy |
37,494
+33,517
| +843% | +$381K | 0.04% | 438 |
|
|
2017
Q3 | $49K | Buy |
3,977
+701
| +21% | +$6.51K | ﹤0.01% | 1110 |
|
|
2017
Q2 | $27K | Buy |
+3,276
| New | +$26.8K | ﹤0.01% | 1196 |
|
|
2016
Q3 | – | Sell |
-25,200
| Closed | -$90K | – | 1942 |
|
|
2016
Q2 | $90K | Buy |
25,200
+12,200
| +94% | +$39.8K | 0.01% | 801 |
|
|
2016
Q1 | $38K | Buy |
13,000
+1,200
| +10% | +$3.6K | 0.01% | 1021 |
|
|
2015
Q4 | $50K | Buy |
+11,800
| New | +$53.9K | 0.01% | 1049 |
|
|
2015
Q2 | – | Sell |
-4,400
| Closed | -$32.5K | – | 2207 |
|
|
2015
Q1 | $32K | Buy |
+4,400
| New | +$31.3K | ﹤0.01% | 1649 |
|
|
2014
Q3 | – | Sell |
-30,200
| Closed | -$138K | – | 2262 |
|
|
2014
Q2 | $138K | Buy |
30,200
+19,900
| +193% | +$82.3K | 0.02% | 912 |
|
|
2014
Q1 | $48K | Buy |
+10,300
| New | +$51.8K | 0.01% | 1327 |
|
Other funds holding ARRY
Prelude Capital Management's ARRY Position: Q3 2019 in Review
Prelude Capital Management sold out of Array Biopharma Inc (ARRY) in Q3 2019, closing a stake of 564,244 shares — an estimated $26.1M sold.
Prelude Capital Management first reported a position in ARRY in Q1 2014 and held it in 14 quarters. The position peaked at $26.1M in Q2 2019. 1 fund tracked by Wall St. Rank holds ARRY as of Q3 2019.
- Prelude Capital Management reported no remaining Array Biopharma Inc position as of Q3 2019 after selling out during the quarter.
- Prelude Capital Management sold 564,244 Array Biopharma Inc shares in Q3 2019, an estimated $26.1M.
- Prelude Capital Management first reported a position in Array Biopharma Inc in Q1 2014 and held it in 14 quarters.
- Prelude Capital Management's Array Biopharma Inc position peaked at $26.1M in Q2 2019.
- 1 fund tracked by Wall St. Rank held Array Biopharma Inc as of Q3 2019.
Based on Prelude Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.